**123I-MIBG Scintigraphy Utility as a biomarker for Prodromal Dementia with Lewy Bodies (SUPERB) - CONTROLS**

This study aims to examine the symptoms and brain changes which are associated with very early memory problems. We call this early period as the prodromal phase and by studying these very early changes we can detect and diagnose problems earlier. To make sure that the changes we see are not simply due to normal, healthy ageing, we would like to include in our study some volunteers without any memory problems. Healthy volunteers make up the “control” group.

### Visit 1
The initial assessment would take place in your own home (or at our clinic in Newcastle, if preferred). A researcher would explain the study to you and answer any questions you might have. We would ask for your written consent to participate. We would ask questions about your memory and mood.

### Visit 2
On the second visit, volunteers would have:

<table>
<thead>
<tr>
<th>Medical review</th>
<th>Bloods</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) An interview with the doctor and a brief physical examination</td>
<td>(2) Have blood samples taken</td>
</tr>
</tbody>
</table>

### Visit 3
**MIBG scan at the RVI**
This visit would last about 5 hours. You would have an injection of about a teaspoon of radioactive liquid. This would be followed by 2 scans.

### Visit 4
**FP-CIT scan (also known as a DaTSCAN) at the RVI**
The DaTSCAN visit would last about 5-7 hours.

### Visit 5
On the last baseline visit we would like to look at:

| (1) Your brain activity by completing an EEG. | (2) Structural images of your brain by performing a MRI scan. | (3) There is an OPTION to have a lumbar puncture |

### Annual follow-up visit
After one year, we would to visit study volunteers either at home or at CARU for a single visit to assess memory and mood. We would like to carry out a follow-up visits every year for 4 years following completion of the baseline visits. We would also like to repeat the FP-CIT (DaTSCAN)

This is a very brief summary of what is involved. Further information is provided in the patient information sheets which you should read before deciding whether or not to take part in this study.

If you would like further information please contact Professor Alan Thomas, or any member of the research team at the Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL

**Telephone: 0191 208 1322** or **Email: SUPERB@ncl.ac.uk**